logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5127.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5127.produseast1
Diagnostic performance of the novel FujiLAM assay to detect tuberculosis in HIV-positive patients | Conference Material / Abstract | MSF Science Portal
Conference Material
|Abstract

Diagnostic performance of the novel FujiLAM assay to detect tuberculosis in HIV-positive patients

Huerga H
Download

Similar Content
Loading...
Loading...
Loading...
Abstract
BACKGROUND
The novel urine-based point-of-care FujiLAM assay is a promising tool for tuberculosis (TB) diagnosis. We prospectively assessed the diagnostic accuracy of FujiLAM and we compared it to the WHO-recommended Abbott TB-LAM assay in people living with HIV (PLHIV) in Uganda, Kenya, Mozambique, and South Africa.

METHODS
Diagnostic prospective study including ambulatory HIV-positive individuals (≥15 years) with signs or symptoms of TB irrespective of their CD4 count, and asymptomatic patients with advanced HIV disease. All patients received clinical examination, FujiLAM and Abbott TB-LAM, GeneXpert MTB/RIF Ultra (sputum or urine), culture (sputum) and chest X-ray. Accuracy of the assays was evaluated against a microbiologically reference standard (confirmed TB defined by any positive culture or Xpert Ultra result).

FINDINGS
We included 1575 patients: 1031 Group 1 and 544 Group 2 with median CD4 count 528 cells/µL [IQR: 272-770] and 128 cells/µL [IQR: 66-181], and microbiologically confirmed TB in 12.4% (96/776) and 5.5% (18/330), respectively. The overall sensitivities of FujiLAM and Abbott TB-LAM were respectively, 59.6% (95%CI 50.1- 68.7) and 40.4% (95CI 31.3-49.9), p-value<0.001. FujiLAM sensitivity was higher than that of Abbott TB-LAM among patients with CD4<200cells/µL, 69.2% (95%CI 56.6-80.1%) and 52.3% (95CI 39.5-64.9), p-value=0.035, respectively, and among patients with CD4≥200cells/µL, 46.9% (95%CI 32.5-61.7) and 24.5% (95CI 13.3-38.9), p-value=0.019, respectively. The specificities of FujiLAM and Abbott TB-LAM were 86.6% (95%CI 84.3-88.7) and 86.4% (95%CI 84.1-88.5) respectively.

INTERPRETATION
This large prospective study shows the higher sensitivity of FujiLAM compared to Abbott TB-LAM, and its potential significant benefit in rapid and simple TB diagnosis of PLHIV.

These abstracts are not to be quoted for publication

Countries

Kenya Mozambique South Africa Uganda

Subject Area

tuberculosisdiagnosticsHIV/AIDS

Languages

English
Published Date
29 Jun 2022
Conference
TB Research Dissemination Workshop, Epicentre Uganda